Checking blood levels of targeted drugs for digestive cancers
Part of Cancer, Digestive system clinical trials.
This trial monitors how your prescribed targeted cancer medicine moves through your body by doing extra blood tests. The goal is to understand the drug’s levels and dosing in people with advanced digestive cancers, so treatment can be better managed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have advanced digestive cancer, with confirmed diagnosis, and your usual plan includes one specific targeted drug (listed in the study)
- Your cancer can be measured on scans (measurable disease)
- You can do the extra study follow-up, including required blood samples during treatment
- You have signed consent (or a trusted independent person can confirm consent if you can’t sign yourself)
- You are able to use a social security system (or an equivalent program)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a simple blood test can help track advanced colorectal cancer over time. It may help doctors see how well treatment is working and when the disease might progress, without needing repeated scans or biopsies.
This Phase 3 study tests whether giving treatment based on a positive blood test for “minimal cancer signals” (ctDNA) can help people with certain GI cancers stay cancer-free longer. It focuses on people who have finished curative-intent therapy and currently have no visible disease on scans, but their blood test is still positive.
This study builds a clinical and biological database for people newly diagnosed with certain cancers. It may help doctors better understand cancer patterns and improve future care, and it involves agreeing to extra blood samples.
This study tests whether a simple blood test can track how well your colorectal cancer is responding to first-line chemotherapy. By monitoring cancer markers in your blood, doctors may be able to detect treatment changes earlier than traditional imaging.
This study follows how cancer responds to standard (usual) treatment by using blood samples and de-identified health data. It may help researchers understand whether “liquid biopsy” blood testing can reflect how well therapy is working.
This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA methylation) can help monitor how well treatment is working in people with colorectal cancer that has spread. If you are getting radiation and chemotherapy (with or without an immunotherapy drug), this trial may help your doctor see if the treatment is working sooner.
Hear when a new Digestive Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.